Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab

Passardi, Alessandro; Azzali, Irene; Bittoni, Alessandro; Marisi, Giorgia; Rebuzzi, Francesca; Molinari, Chiara; Bartolini, Giulia; Matteucci, Laura; Sullo, Francesco Giulio; Debonis, Silvia Angela; Gallio, Chiara; Monti, Manlio; Valgiusti, Martina; Muratore, Margherita; Rapposelli, Ilario Giovanni; Ulivi, Paola; Frassineti, Giovanni Luca

doi:10.1177/17588359231212184

Cited by 7 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Warburg effect refers to the ability of cancer cells to derive energy through glycolysis even under aerobic conditions. Therefore, elevated serum LDH levels may reflect increased cancer cell activation and are associated with poor prognosis in cancer patients [34]. The results of our study are compatible with those of previous studies [19,23,24,[32][33][34][35], and LDH was identified as a factor associated with unfavorable outcomes in extensive-stage SCLC patients who received first-line anti-PD-L1 ICIs combined with chemotherapy.…”

Section: Discussionsupporting

confidence: 91%

“…Therefore, elevated serum LDH levels may reflect increased cancer cell activation and are associated with poor prognosis in cancer patients [34]. The results of our study are compatible with those of previous studies [19,23,24,[32][33][34][35], and LDH was identified as a factor associated with unfavorable outcomes in extensive-stage SCLC patients who received first-line anti-PD-L1 ICIs combined with chemotherapy. The three female patients in this study had significantly shorter OS than the male patients.…”

Section: Discussionsupporting

confidence: 91%

“…LDH is an essential enzyme in glycolysis and functions through catalyzing the conversion of pyruvate to lactate. Elevated serum LDH levels have been used as an inflammatory index [34]. The Warburg effect refers to the ability of cancer cells to derive energy through glycolysis even under aerobic conditions.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Hsu,

Wu,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Real-world clinical experience of using anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (SCLC) patients has rarely been reported. In this study, we aimed to perform a retrospective multicenter clinical analysis of extensive-stage SCLC patients receiving first-line therapy with anti-PD-L1 ICIs combined with chemotherapy. Between November 2018 and March 2022, 72 extensive-stage SCLC patients receiving first-line atezolizumab or durvalumab in combination with chemotherapy, according to the cancer center databases of Linkou, Chiayi, and Kaohsiung Chang Gung Memorial Hospitals, were retrospectively included in the analysis. Twenty-one patients (29.2%) received atezolizumab and fifty-one (70.8%) received durvalumab. Objective response (OR) and disease control (DC) rates of 59.7% and 73.6%, respectively, were observed with first-line ICI plus chemotherapy. The median progression-free survival (PFS) was 6.63 months (95% confidence interval (CI), 5.25–8.02), and the median overall survival (OS) was 16.07 months (95% CI, 15.12–17.0) in all study patients. A high neutrophil-to-lymphocyte ratio (NLR; >4) and a high serum lactate dehydrogenase (LDH) concentration (>260 UL) were identified as independent unfavorable factors associated with shorter OS in the multivariate analysis. Regarding safety, neutropenia was the most common grade 3 treatment-related adverse event (AE), but no treatment-related deaths occurred in the study patients. First-line anti-PD-L1 ICIs combined with chemotherapy are effective and safe for male extensive-stage SCLC patients. Further therapeutic strategies may need to be developed for patients with unfavorable outcomes (e.g., baseline high NLR and serum LDH level).

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Hsu,

Wu,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Furthermore, research has shown that SII is associated with a heightened risk of mortality in adults with asthma 33 . Within oncology, studies established SII as an independent prognostic factor for overall mortality, underscoring its potential utility as a prognostic marker 34 , 35 . In cardiac surgery, a meta-analysis involving over 3245 patients revealed that a high preoperative SII significantly predicts an increased risk of postoperative atrial fibrillation, suggesting its value as a predictive biomarker 36 .…”

Section: Discussionmentioning

confidence: 99%

“…It is derived from a formula incorporating levels of specific immune system markers obtained from complete blood counts, specifically, (platelets × neutrophils) / lymphocytes 7 . Traditionally, SII has been utilized as a mortality predictor for patients with various tumors 6 , 7 , 34 , 36 , cerebrovascular diseases 8 , 9 , 11 , and cardiovascular conditions 9 , 10 , 12 . The scope of SII's application has been broadening, with recent research indicating its potential in forecasting disease severity and monitoring the efficacy of treatments 13 – 17 .…”

Section: Introductionmentioning

confidence: 99%

Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis

Yin,

Zhang,

Zou

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The systemic immune-inflammation index (SII), a metric reflecting systemic inflammatory response and immune activation, remains underexplored concerning its correlation with mortality among rheumatoid arthritis (RA) patients. This study aimed to delineate the association between SII and both all-cause and cardiovascular mortality within the cohort of American adults diagnosed with RA, utilizing data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018. The investigation extracted data from NHANES cycles between 1999 and 2018, identifying RA patients through questionnaire responses. The SII was computed based on complete blood counts, employing the formula: (platelets × neutrophils) / lymphocytes. The optimal SII cutoff value for significant survival outcomes was determined using maximally selected rank statistics. Multivariable Cox proportional hazards models assessed the relationship between SII levels and mortality (all-cause and cardiovascular) among RA patients, with subgroup analyses examining potential modifications by clinical confounders. Additionally, restricted cubic spline (RCS) analyses were conducted to explore the linearity of the SII-mortality association. The study encompassed 2070 American adults with RA, among whom 287 exhibited a higher SII (≥ 919.75) and 1783 a lower SII (< 919.75). Over a median follow-up duration of 108 months, 602 participants died. After adjustments for demographic, socioeconomic, and lifestyle variables, a higher SII was associated with a 1.48-fold increased risk of all-cause mortality (hazard ratio [HR] = 1.48, 95% confidence interval [CI] 1.21–1.81, P < 0.001) and a 1.51-fold increased risk of cardiovascular mortality (HR = 1.51, 95% CI 1.04–2.18, P = 0.030) compared to a lower SII. Kaplan–Meier analyses corroborated significantly reduced survival rates within the higher SII cohort for both all-cause and cardiovascular mortality (Pall-cause mortality < 0.0001 and Pcardiovascular mortality = 0.0004). RCS analyses confirmed a positive nonlinear relationship between SII and mortality rates. In conclusion, the SII offers a straightforward indicator of the equilibrium between detrimental innate inflammation and beneficial adaptive immunity. Our investigation, utilizing a comprehensive and nationally representative sample, reveals that elevated SII levels independently forecast a greater risk of mortality from all causes, as well as cardiovascular-specific mortality, in individuals suffering from RA. These insights underscore the clinical relevance of the SII as an affordable and readily accessible biomarker. Its incorporation into regular clinical practice could significantly enhance the precision of risk assessment and forecasting for patients with RA, facilitating more tailored and effective management strategies. Specifically, patients with high SII levels could be identified for more stringent cardiovascular risk management, including closer monitoring, lifestyle interventions, and aggressive pharmacological treatments to mitigate their increased risk of mortality.

show abstract

Relationship between systemic immune-inflammation index and long-term all-cause and cause-specific mortality among adult asthma patients: a population—based study

Luo,

Chen,

Zhu

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background Persistent inflammation in the airways is a hallmark of asthma, and researchers have extensively explored various inflammatory indicators that contribute to the condition. Despite this, there is limited research on the relationship between the systemic immune-inflammation index (SII), a novel marker of inflammation, and overall mortality rates as well as mortality rates due to specific causes in individuals with asthma. Methods We analyzed data from the National Health and Nutrition Examination Survey (NHANES) covering a 20-year period, from 1999 to 2018. To examine the association between SII and mortality rates in asthma patients, we used a combination of statistical methods, including weighted Kaplan-Meier analysis and multivariate-adjusted Cox analysis. Additionally, we applied restricted cubic spline (RCS) analysis to investigate the potential non-linear relationship between these variables. To further validate our findings, we performed subgroup and sensitivity analyses to ensure the reliability of the results. Results This study analyzed data from 5,384 individuals with asthma, finding a link between increased SII levels and a higher risk of death from all-cause, cardiovascular disease and respiratory disease, but no association with cancer mortality. There were J-shaped non-linear relationships between SII and all-cause, cardiovascular and respiratory diseases mortality in asthma patients. The inflection points were 326, 350 and 355, respectively. Below these inflection points, each 100-unit increase in SII was associated with a decrease in mortality by 8%, 11% and 10%, while above these thresholds, mortality rates increased by 4%, 4%, and 3%, respectively. Subgroup analyses showed that SII was a significant predictor of all-cause mortality across various subgroups, and sensitivity analyses confirmed these findings, with the highest SII group consistently showing higher mortality rates for all-cause, cardiovascular, and respiratory disease mortality in the fully adjusted model. Conclusions Our study initially demonstrated a strong link between elevated SII levels and a higher risk of death from all-cause, cardiovascular disease, and respiratory disease in individuals with asthma. Furthermore, our analysis showed that the relationship between SII and mortality rates in asthma patients followed a non-linear, J-shaped pattern for all-cause, cardiovascular, and respiratory disease mortality. Clinical trial number Clinical trial number not applicable. Supplementary Information The online version contains supplementary material available at 10.1186/s12890-024-03452-5.

show abstract

Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab

Cited by 7 publications

References 42 publications

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis

Relationship between systemic immune-inflammation index and long-term all-cause and cause-specific mortality among adult asthma patients: a population—based study

Contact Info

Product

Resources

About